OncologyOnline.net

Oncology Xagena

Longer term ( 18 month ) survival data from CheckMate -057, an open-label, randomized phase 3 study evaluating Nivolumab [ Opdivo ] ( n=292 ) versus Docetaxel [ Taxotere ] ( n=290 ) in previously trea ...


In 2020 the percentage of patients with a diagnosis of cancer in people with more than 65 years will exceed 70% and 28% in ethnic minorities. The treatment of cancer in these populations is challengin ...


Results from CheckMate -025, a phase 3 study comparing Nivolumab ( Opdivo ) to Everolimus ( Afinitor ) in advanced renal cell carcinoma ( RCC ) after prior anti-angiogenic treatment, showed a signific ...


Positive results from two phase II studies that evaluated the investigational cancer immunotherapy Atezolizumab ( anti-PDL1; MPDL3280A ) in people with advanced non-small cell lung cancer ( NSCLC ) we ...


Early results from a pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy Atezolizumab ( anti-PDL1; MPDL3280A ) in people with locally advanced or metastatic urothelial car ...


New data from KEYNOTE-001, a phase 1b study evaluating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in naïve and previously-treated patients with advanced non-small cell lung cancer ( NSCLC ) wer ...


A Committee of the American Society of Clinical Oncology NSCLC Expert Panel carried out a systematic review of randomized controlled trials from January 2007 to February 2014 to provide evidence-base ...


Although activating mutations in the epidermal growth factor receptor ( EGFR ) gene are predictive markers for response to EGFR inhibitors, 30-40% of EGFR-mutant non-small cell lung cancer ( NSCLC ) p ...


T-DM1 ( Trastuzumab emtansine; Kadcyla ) treatment resulted in non-inferior, but not-superior, progression-free survival ( PFS ) compared with Trastuzumab plus a taxane ( HT ) in patients with locally ...


Results from two pivotal studies ( NP28673 and NP28761 ) have showen Alectinib, an oral investigational anaplastic lymphoma kinase inhibitor ( ALKi ), shrank tumours ( overall response rate; ORR: 50% ...


The immune-modulating effects of radiotherapy ( XRT ) have gained considerable interest, and there have been multiple reports of synergy between radiotherapy and immunotherapy. However, additional p ...


Management of the neck in early oral cancers has been a matter of debate with clinical equipoise between elective ( END ) or therapeutic neck dissection ( TND ). This is a prospective phase III RC ...


Cancer Drugs Fund ( CDF ) Panel has assessed the application was for single agent Pemetrexed ( Alimta ) to remain in the CDF as maintenance treatment for patients with locally advanced or metastatic ...


A new study has provided the first evidence that the mediator complex subunit 15 ( MED15 ) may play a crucial role in the pathophysiology of head and neck squamous cell carcinoma ( HNSCC ). MED15 ov ...


Axillary lymph node evaluation is performed frequently in women with ductal carcinoma in situ breast cancer, despite recommendations generally against such an assessment procedure in women with locali ...